The high prevalence of STIs throughout the world makes it a major area for diagnostic development, especially for asymptomatic infections which are still transmissible. According to WHO data, more than 1 million STIs take place every day contributing to an annual tally of 375 million infections from chlamydia, gonorrhea, syphilis, and trichomoniasis alone. This does not include the viral STIs like human immunodeficiency virus (HIV), herpes simplex virus (HSV), or human papillomavirus (HPV). Infection with one STI frequently increases the likelihood of additional STIs.
While education about safe practices are key infection prevention strategies, significant healthcare challenges remain in the face of poor access to timely testing, lack of vaccines, and complications from STIs; for example, globally, HPV infections are estimated to result in 570,000 cases of cervical cancer each year. In recent years, a vaccine to HPV has become available, raising hopes that cervical cancer numbers will be significantly reduced in the future. However, much research remains to be done as the only other vaccine against an STI is for hepatitis B.
In addition to comprehensive immune system antibody portfolios, Bio-Rad supplies a range of antibodies suitable for basic research, vaccine development, and diagnostics for STIs.
Key sexually transmitted infections and pathogens include:
|Chlamydia ▸||Cytomegalovirus ▸||Hepatitis A ▸||Hepatitis B ▸|
|Hepatitis C ▸||Herpes ▸||HIV ▸||HPV ▸|
|Neisseria gonorrhoeae ▸||Treponema pallidum ▸||Trichomonas ▸|